CY1109062T1 - Μεθοδοι ανιχνευσεως και αναστολης της αγγειογενεσεως - Google Patents

Μεθοδοι ανιχνευσεως και αναστολης της αγγειογενεσεως

Info

Publication number
CY1109062T1
CY1109062T1 CY20091100513T CY091100513T CY1109062T1 CY 1109062 T1 CY1109062 T1 CY 1109062T1 CY 20091100513 T CY20091100513 T CY 20091100513T CY 091100513 T CY091100513 T CY 091100513T CY 1109062 T1 CY1109062 T1 CY 1109062T1
Authority
CY
Cyprus
Prior art keywords
tissue
integrin
angiogenesis
agent
methods
Prior art date
Application number
CY20091100513T
Other languages
English (en)
Inventor
Judith A Varner
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22187621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109062(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of CY1109062T1 publication Critical patent/CY1109062T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μεθόδους για τη μείωση ή την αναστολή της αγγειογενέσεως σε έναν ιστό, δι' επαφής της ιντεγρίνης α5β1 εντός του ιστού με έναν παράγοντα ο οποίος παρεμβάλλεται στην επιλεκτική δέσμευση της ιντεγρίνης α5β1 από ένα πρόσδεμα εκφραζόμενο στον ιστό· και μεθόδους εντοπισμού της αγγειογενέσεως σε έναν ιστό, δι' επαφής του ιστού με έναν παράγοντα ο οποίος συνδέεται επιλεκτικά με μία ιντεγρίνη α5β1 και ανιχνεύσεως της επιλεκτικής συνδέσεως του παράγοντα με την ιντεγρίνη α5β1 που συσχετίζεται με ένα αιμοφόρο αγγείο εντός του ιστού. Παρέχονται επίσης μέθοδοι διαγνώσεως μίας παθολογικής καταστάσεως χαρακτηριζόμενης από αγγειογένεση σε έναν ιστό ενός ατόμου. Η εφεύρεση παρέχει περαιτέρω μεθόδους μειώσεως ή αναστολής της αγγειογενέσεως σε έναν ιστό ενός ατόμου, δια χορηγήσεως στο άτομο ενός παράγοντα ο οποίος παρεμβάλλεται στην επιλεκτική δέσμευση της ιντεγρίνης α5β1 από ένα πρόσδεμα εκφραζόμενο στον ιστό· και μεθόδους μειώσεως της σοβαρότητας μίας παθολογικής καταστάσεως σχετιζόμενης με την αγγειογένεση σε ένα άτομο, δια χορηγήσεως στο άτομο ενός παράγοντα ο οποίος παρεμβάλλεται σε επιλεκτική δέσμευση της ιντεγρίνης α5β1 από ένα πρόσδεμα σε έναν ιστό σχετιζόμενο με την παθολογική κατάσταση. Η εφεύρεση παρέχει επίσης μεθόδους ταυτοποιήσεως ενός παράγοντα ο οποίος μειώνει ή αναστέλλει την αγγειογένεση τη σχετιζόμενη με την έκφραση της ιντεγρίνης α5β1 σε έναν ιστό δι' επαφής ενός ιστού ο οποίος εμφανίζει αγγειογένεση σχετιζόμενη με έκφραση ιντεγρίνης α5β1 με έναν παράγοντα και ανιχνεύσεως της μειώσεως ή της αναστολής της αγγειογενέσεως στον ιστό.
CY20091100513T 1998-05-08 2009-05-14 Μεθοδοι ανιχνευσεως και αναστολης της αγγειογενεσεως CY1109062T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8485098P 1998-05-08 1998-05-08
EP99922828A EP1075277B2 (en) 1998-05-08 1999-05-07 Methods for detecting and inhibiting angiogenesis

Publications (1)

Publication Number Publication Date
CY1109062T1 true CY1109062T1 (el) 2014-07-02

Family

ID=22187621

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100513T CY1109062T1 (el) 1998-05-08 2009-05-14 Μεθοδοι ανιχνευσεως και αναστολης της αγγειογενεσεως

Country Status (11)

Country Link
EP (3) EP2327451B1 (el)
JP (2) JP2002514605A (el)
AT (1) ATE423570T1 (el)
AU (1) AU746662B2 (el)
CA (1) CA2328414C (el)
CY (1) CY1109062T1 (el)
DE (1) DE69940465D1 (el)
DK (1) DK1075277T4 (el)
ES (1) ES2322723T5 (el)
PT (1) PT1075277E (el)
WO (1) WO1999058139A2 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
GB9909392D0 (en) * 1999-04-24 1999-06-23 Imp Cancer Res Tech Treatment, imaging and diagnosis of disease
US7101975B1 (en) 1999-07-13 2006-09-05 University Of Southern California Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins
ES2327812T3 (es) * 1999-07-13 2009-11-04 University Of Southern California Nuevos metodos y composiciones para inhibir la angiogenesis utilizando bases antagonistas de mmp-9 y/o integrinas beta-1.
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
JP4667873B2 (ja) * 2002-07-16 2011-04-13 アベンティス・ファーマシューティカルズ・インコーポレイテッド α５β１およびその細胞生存経路を調節する能力
KR20110140143A (ko) * 2002-11-26 2011-12-30 애보트 바이오테라퓨틱스 코포레이션 혈관형성을 조절하는 α5β1 인테그린에 대한 키메라성 및 인간화 항체
US7276589B2 (en) 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7285268B2 (en) 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
EP1755659B1 (en) * 2004-03-24 2011-11-02 Abbott Biotherapeutics Corp. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
RU2007118385A (ru) * 2004-11-22 2008-12-27 Джи-И Хелткер АС (NO) Контрастные агенты для направлений доставки во внеклеточный матрикс
DE102005023784A1 (de) * 2005-05-19 2006-11-30 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
MY159375A (en) 2006-03-21 2016-12-30 Genentech Inc Combinatorial therapy
US7973138B2 (en) 2007-09-26 2011-07-05 Genentech, Inc. Antibodies
DK2252627T3 (en) * 2008-01-24 2017-08-14 Esperance Pharmaceuticals MERGER CONSTRUCTION WITH LYTIC DOMAIN AND METHOD FOR PRODUCING AND USING SAME.
EP2411411B1 (en) 2009-03-25 2016-08-31 F.Hoffmann-La Roche Ag Novel anti-alpha5beta1 antibodies and uses thereof
US20110319335A1 (en) 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
KR20140030153A (ko) * 2011-03-23 2014-03-11 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 항-인테그린을 사용하여 항혈관 형성 요법을 개선하기 위한 방법 및 조성물
US8946159B2 (en) 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
EP3365353B1 (en) 2015-10-23 2023-11-22 Universiteit Twente Integrin binding peptides and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
CA2249733A1 (en) * 1996-03-15 1997-09-18 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
EP3031172B1 (en) 2013-08-07 2017-06-28 AB Initio Technology LLC Managing data feeds

Also Published As

Publication number Publication date
DK1075277T4 (da) 2012-12-17
AU3973499A (en) 1999-11-29
EP2327451A3 (en) 2012-05-09
EP1075277A2 (en) 2001-02-14
ES2322723T5 (es) 2013-03-11
DE69940465D1 (de) 2009-04-09
JP2009051815A (ja) 2009-03-12
JP4312822B2 (ja) 2009-08-12
EP2327451A2 (en) 2011-06-01
PT1075277E (pt) 2009-05-08
DK1075277T3 (da) 2009-05-04
WO1999058139A3 (en) 2000-02-10
CA2328414C (en) 2014-04-15
ATE423570T1 (de) 2009-03-15
EP2044955A2 (en) 2009-04-08
ES2322723T3 (es) 2009-06-25
JP2002514605A (ja) 2002-05-21
EP2327451B1 (en) 2013-10-23
WO1999058139A2 (en) 1999-11-18
EP2044955A3 (en) 2009-04-29
EP1075277B1 (en) 2009-02-25
CA2328414A1 (en) 1999-11-18
EP1075277B2 (en) 2012-10-31
AU746662B2 (en) 2002-05-02

Similar Documents

Publication Publication Date Title
CY1109062T1 (el) Μεθοδοι ανιχνευσεως και αναστολης της αγγειογενεσεως
DE69928809D1 (de) Differentielle diagnose von neurodegeneration
DE69510336T2 (de) Verfahren zur diagnose von praeklampsie
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
FI941832A (fi) Menetelmiä NMR:llä havaittavien ksenobioottisten yhdisteiden in vivo määrittämiseksi
ATE415632T1 (de) Verfahren zur diagnose und behandlung von morbus crohn
TR200101148T2 (tr) Dışkı maddesi için algılayıcılar içeren hijyenik eşyalar.
WO2000026251A3 (en) A COMPLEX OF A CHAPERONE WITH ss-AMYLOID AND METHODS EMPLOYING THIS COMPLEX
DE60234958D1 (de) Psoriasin-expression durch brustepithelzellen
DE60036935D1 (de) Diagnostisches Verfahren für Eierstock- und Endometriumtumore basierend auf dem Nachweis des L1-Adhäsionsmoleküls
EP1731913A3 (en) Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases
WO1998046993A3 (en) Method for diagnosing cancer by measuring the presence of creatine kinase inhibitor
BR0115689A (pt) Análise de expressão de inibidor de diferenciação de ácidos nucléicos e polipeptìdeos úteis na diagnose e tratamento de câncer da próstata
WO2001038581A3 (en) Vigilance nucleic acids and related diagnostic, screening and therapeutic methods
FI951778A0 (fi) Menetelmä allergian toteamiseksi
AU4937800A (en) Diagnosis of chronic obstructive pulmonary disease
DE69912453D1 (de) Verfahren und materialien zur diagnose instabiler angina
ES2168378T3 (es) Determinacion de tripsinogeno-2 libre y en forma de complejo.
ATE362545T1 (de) Screening-verfahren für substanzen zur behandlung von diabetes
TR200003887T2 (tr) Leptinin fizyolojik etkisini taklit eden, kuvvetlediren veya önleyen veya bir bileşiğin tespit edilmesi için metod
UA36457A (uk) Спосіб діагностики гострої непрохідності тонкої кишки
Bashkov et al. ALTERED INTERACTION OF THROMBIN AND ANTITHROMBIN III WITH THE VASCULAR WALL